PRAME and melanoma: Lezcano and colleagues (2018) performed an IHC analysis for preferentially expressed antigen in melanoma (PRAME) protein expression in melanocytic tumors and found that 83.2% of primary cutaneous melanomas regularly and diffusely expressed PRAME [28].